Chen, Sujun http://orcid.org/0000-0002-1941-3951
Petricca, Jessica
Ye, Wenbin http://orcid.org/0000-0002-7811-2710
Guan, Jiansheng
Zeng, Yong
Cheng, Nicholas
Gong, Linsey http://orcid.org/0000-0003-0400-3180
Shen, Shu Yi http://orcid.org/0000-0001-7036-2291
Hua, Junjie T.
Crumbaker, Megan
Fraser, Michael
Liu, Stanley http://orcid.org/0000-0001-6851-0857
Bratman, Scott V. http://orcid.org/0000-0001-8610-4908
van der Kwast, Theodorus http://orcid.org/0000-0001-8640-5786
Pugh, Trevor http://orcid.org/0000-0002-8073-5888
Joshua, Anthony M. http://orcid.org/0000-0001-5159-4580
De Carvalho, Daniel D.
Chi, Kim N.
Awadalla, Philip http://orcid.org/0000-0001-9946-6393
Ji, Guoli
Feng, Felix http://orcid.org/0000-0002-0963-7687
Wyatt, Alexander W. http://orcid.org/0000-0003-2399-0329
He, Housheng Hansen http://orcid.org/0000-0003-2898-3363
Funding for this research was provided by:
Princess Margaret Cancer Foundation (886012001223)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (142246, 152863, 152864 and 159567)
Terry Fox Research Institute (1090)
Prostate Cancer Canada (TAG2018-2061)
Article History
Received: 27 January 2022
Accepted: 7 October 2022
First Online: 29 October 2022
Competing interests
: D.D.D.C. and S.Y.S. are listed as inventors/contributors on patent (CA3022606A1, Methods of capturing cell-free methylated DNA and uses of same) related to the cfMeDIP-seq technology. D.D.D.C. received research funds from Pfizer and Nektar therapeutics. D.D.D.C. is co-founder and shareholder of Adela. All the other authors declare no competing interests.